{"nctId":"NCT00577655","briefTitle":"Albuterol HFA MDI in Pediatric Participants With Asthma","startDateStruct":{"date":"2007-08"},"conditions":["Asthma"],"count":103,"armGroups":[{"label":"Albuterol","type":"EXPERIMENTAL","interventionNames":["Drug: Albuterol","Drug: Proventil® HFA"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Proventil® HFA"]}],"interventions":[{"name":"Albuterol","otherNames":["ProAir® HFA","Albuterol Sulfate"]},{"name":"Placebo","otherNames":[]},{"name":"Proventil® HFA","otherNames":["albuterol sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female child aged 4-11 years, inclusive Asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening.\n\nExclusion Criteria:\n\n* Hospitalization for acute asthma exacerbation greater than two years in 12 months prior to screening and/or received ER treatment or hospitalization for asthma exacerbation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Observed up to Two Hours Post Dose (FEV1max%0-2) on Day 22","description":"The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (±2 hrs).\n\nThe maximum percent change from baseline in FEV1 observed up to 2 hours following completion of dosing using Day 22 baseline. The baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.849","spread":"1.005"},{"groupId":"OG001","value":"9.353","spread":"1.017"}]}]}]},{"type":"PRIMARY","title":"Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) Observed up to Two Hours Post Dose (PEFmax%0-2) on Day 22","description":"The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (±2 hrs).\n\nThe maximum percent change from baseline in the PEF observed up to 2 hours following completion of dosing using Day 22 baseline. The baseline PEF was defined as the average of the test-day pre-dose baseline PEF values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.558","spread":"1.878"},{"groupId":"OG001","value":"12.127","spread":"1.907"}]}]}]},{"type":"SECONDARY","title":"Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1) up to Two Hours Post-Dose (FEV1max%0-2, %) on Study Days 1 and 22 Using Observed Cases","description":"The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (±2 hrs).\n\nThe maximum percent change from baseline in FEV1 observed up to 2 hours following completion of dosing using test day baseline. The baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.621","spread":"1.072"},{"groupId":"OG001","value":"8.085","spread":"1.075"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.601","spread":"1.072"},{"groupId":"OG001","value":"9.534","spread":"1.119"}]}]}]},{"type":"SECONDARY","title":"Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF) up to Two Hours Post-Dose (PEFmax%0-2) on Study Days 1 and 22 Using Observed Cases","description":"The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. A standardized spirometer was used with the subject in the sitting or standing position (orientation had to be consistent for each subject during study visits) and wearing a nose clip. Whenever possible, evaluations were performed by the same respiratory therapist on the same calibrated spirometer at approximately the same time (±2 hrs).\n\nThe maximum percent change from baseline in the PEF observed up to 2 hours following completion of dosing on study days 1 and 22. The baseline PEF was defined as the average of the test-day pre-dose baseline PEF values.\n\nThe reason for the two primary endpoints was that FEV1 is difficult to obtain in children below 7 years of age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.040","spread":"1.982"},{"groupId":"OG001","value":"12.468","spread":"2.004"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.776","spread":"1.997"},{"groupId":"OG001","value":"12.994","spread":"2.076"}]}]}]},{"type":"SECONDARY","title":"Baseline Adjusted Area-under-the-Effect Curve for Percent of Predicted Forced Expiratory Volume in One Second (FEV1) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines","description":"The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. Values are then expressed as the percentage of FE1 values predicted for a 'normal' population. Predicted FEV1 values were computed and adjusted for age, height and gender according to Eigen et al. for subjects 4-5 years of age and to Quanjer et al. for subjects aged 6-11 years using American Thoracic Society (ATS) criteria.\n\nThe area under-the-effect curves for percent-predicted FEV1 were calculated according to the trapezoidal rule and were based on actual (not scheduled) measurement times.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.046","spread":"3.531"},{"groupId":"OG001","value":"21.338","spread":"3.588"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.060","spread":"6.748"},{"groupId":"OG001","value":"24.167","spread":"6.773"}]}]}]},{"type":"SECONDARY","title":"Baseline-Adjusted Area-under-the Effect Curve for Peak Expiratory Flow (PEF) Over 6 Hours Post-dose on Day 22 Using Both Day 1 and Day 22 Baselines","description":"The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown.\n\nThe area under-the-effect curves for PEF were calculated according to the trapezoidal rule and were based on actual (not scheduled) measurement times.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.82","spread":"17.486"},{"groupId":"OG001","value":"90.693","spread":"17.753"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.42","spread":"25.782"},{"groupId":"OG001","value":"96.842","spread":"26.117"}]}]}]},{"type":"SECONDARY","title":"Maximum Percent-Predicted FEV1 (Max PPFEV1, %) Observed up to Two Hours Following Completion of Dosing on Study Days 1 and 22 (Observed Case)","description":"The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. Values are then expressed as the percentage of FE1 values predicted for a 'normal' population. Predicted FEV1 values were computed and adjusted for age, height and gender according to Eigen et al. for subjects 4-5 years of age and to Quanjer et al. for subjects aged 6-11 years using American Thoracic Society (ATS) criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.898","spread":"1.451"},{"groupId":"OG001","value":"89.374","spread":"1.462"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.650","spread":"1.451"},{"groupId":"OG001","value":"90.652","spread":"1.488"}]}]}]},{"type":"SECONDARY","title":"Time To Maximum Forced Expiratory Volume in One Second (FEV1) Over Six Hours Post-Dose On Days 1 and 22","description":"The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters.\n\nTime to maximum FEV1 is defined as the number of minutes required for the baseline FEV1 to increase to the highest FEV1 post dose during the 6 hour observation period.\n\nMedian time and confidence intervals obtained via separate Kaplan-Meier estimates for each study day.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.95","spread":null},{"groupId":"OG001","value":"45.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.54","spread":null},{"groupId":"OG001","value":"61.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Time To Maximum Peak Expiratory Flow (PEF) Over Six Hours Post-Dose On Days 1 and 22","description":"The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown.\n\nTime to maximum PEF is defined as the number of minutes required for the baseline PEF to increase to the highest PEF post-dose for the 6 hour observation period. Median time and confidence intervals obtained via separate Kaplan-Meier estimates for each study day.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.50","spread":null},{"groupId":"OG001","value":"35.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"63.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Responses: Percentage of Participants With a >=15% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22","description":"The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. This outcome counts participants who responded to therapy by obtaining a \\>+15% increase in FEV1 within 30 minutes of dose.\n\nThe baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Responses: Percentage of Participants With a >=12% Increase in Baseline FEV1 Within 30 Minutes Post-Dose on Days 1 and 22","description":"The FEV1 test is conducted by having a person empty their lungs of air into a mouthpiece attached to a sensor that measures the amount of air blown measured in liters. This outcome counts participants who responded to therapy by obtaining a \\>+12% increase in FEV1 within 30 minutes of dose.\n\nThe baseline FEV1 was defined as the average of the two test-day pre-dose baseline FEV1 values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"13.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Responses: Percentage of Participants With a >=15% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22","description":"The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. This outcome counts participants who responded to therapy by obtaining a \\>+15% increase in PEF within 30 minutes of dose.\n\nThe baseline PEF was defined as the average of the two test-day pre-dose baseline PEF values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"19.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"23.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Participant Responses: Percentage of Participants With a >=12% Increase in Baseline PEF Within 30 Minutes Post-Dose on Days 1 and 22","description":"The PEF test is conducted by having a person blow as hard as they can into a mouthpiece attached to a sensor that measures the rate of air blown. This outcome counts participants who responded to therapy by obtaining a \\>+12% increase in PEF within 30 minutes of dose.\n\nThe baseline PEF was defined as the average of the two test-day pre-dose baseline PEF values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null},{"groupId":"OG001","value":"25.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null},{"groupId":"OG001","value":"29.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Weekly Average Highest (Worst) Daily Asthma Symptom Scores for Weeks 1, 2 and 3","description":"Highest daily asthma symptom scores by study week. For this assessment, patients self-evaluate and record on the diary card the following asthma symptoms experienced during the day (i.e. last 12-14 hours): wheeze, shortness of breath, cough, tightness of chest. The worst of these symptoms were scored daily on a four-point scale:\n\n* 0 = No symptoms occurred\n* 1 = Symptom occurred but did not interfere with daily activity\n* 2 = Symptom occurred but was sometimes annoying or interfered with daily activity\n* 3 = Symptom present even at rest and was annoying or interfered with daily activity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.370","spread":"0.070"},{"groupId":"OG001","value":"0.442","spread":"0.070"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.376","spread":"0.070"},{"groupId":"OG001","value":"0.547","spread":"0.071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.336","spread":"0.072"},{"groupId":"OG001","value":"0.474","spread":"0.071"}]}]}]},{"type":"SECONDARY","title":"The Number of Asthma-Related Nocturnal Awakenings Per Week Requiring the Use of Rescue Medication","description":"Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"2.97"},{"groupId":"OG001","value":"1.06","spread":"2.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"3.25"},{"groupId":"OG001","value":"1.00","spread":"2.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"3.82"},{"groupId":"OG001","value":"0.73","spread":"1.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"2.21"},{"groupId":"OG001","value":"1.33","spread":"3.13"}]}]}]},{"type":"SECONDARY","title":"Weekly Average Peak Expiratory Flow (PEF) Obtained Pre-Dose Each Morning","description":"Participants measured their PEF as trained by taking as deep a breath as possible, placing their mouth firmly around the mouthpiece of the flow meter to form a tight seal, and exhaling as hard and as fast as possible. Subjects repeated the process twice at intervals of approximately 30 seconds, and then recorded the highest of the three PEF values on the diary card.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"229.65","spread":"4.800"},{"groupId":"OG001","value":"219.72","spread":"4.854"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229.90","spread":"4.800"},{"groupId":"OG001","value":"218.97","spread":"4.870"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231.28","spread":"4.820"},{"groupId":"OG001","value":"221.73","spread":"4.880"}]}]}]},{"type":"SECONDARY","title":"Weekly Average Number of Puffs of Rescue Medication Taken Each Day for Study Weeks 1, 2 and 3","description":"Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night and the number of puffs of rescue albuterol used during the night after going to bed. At the end of each day, the number of puffs of albuterol rescue medication used during the day were recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.074","spread":null},{"groupId":"OG001","value":"0.075","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.084","spread":null},{"groupId":"OG001","value":"0.088","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.078","spread":null},{"groupId":"OG001","value":"0.088","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Headache","Nasopharyngitis"]}}}